[Perspective] Synthetic immunobiology boosts the IQ of T cells

Science: Current Issue
Pharmaceutical small-molecule drugs are the first “pillar” of modern medicinal therapeutics, with recombinant protein biologics claiming the second pillar. If the emergent third pillar of medicine is cell-based therapeutics, cellular immunotherapy of cancer stands as the pillar's current poster child (1). This approach includes adoptive T cell therapy, which has seen major advances recently. Underlying some of this progress are developments in synthetic tumor recognition receptors. Although it's early days for applied synthetic immunobiology, increasing momentum in this field may soon lead to the application of engineered T cells to a broader spectrum of cancers as well as to infectious and autoimmune diseases. Author: Michael C. Jensen
Read More...

Comments

Popular posts from this blog

Yu Founder On Next Flagship and Open Source Model for Upcoming Smartphones

Vivo V3Max Review

Xiaomi Mi 5 in Pictures